Opportunities
Search

The proposed topic will develop and mature Communications and Networking technologies for Naval operations.Background:A Design for Maritime Superiority (2018) describes an operational architecture for distributed maritime operations (DMO) that "... will provide accurate, timely, and analyzed information to units, warfighting groups, and fleets." A critical component of this architecture is the Naval Tactical Grid (NTG) to connect distributed units into groups and distributed groups into fleets.Communications and networking technologies that can provide seamless, robust, connectivity are key enablers for the NTG. These technologies will be deployed on a variety of platforms, both manned and unmanned, operating under challenging environmental and operational warfare conditions (lack of infrastructure, mobility, spectrum limitations, interference, multipath, atmospherics, jamming, electronic intercept, size/weight/power constraint, etc.) in different domains (land, maritime [includes both surface and undersea], cyber, and space). SuccessfulCommand and Control (C2) and decision making, at all levels of command, for DMO is critically dependent on these communications and networking technologies

Summary: The fiscal year 2026 (FY26) Joint Warfighter Medical Research Program (JWMRP) Military Medical Research and Development Award (MMRDA) mechanism is intended to fund the logical continuation of previous Department of War (DOW)-funded research and development efforts relevant to the FY26 JWMRP that augment and accelerate high-priority medical requirements to meet the needs of Service Members and other Military Health System beneficiaries. The MMRDA supports a wide range of research projects spanning late-stage preclinical studies, late-state technology development efforts, technology demonstration, translational, and clinical research. Projects must be relevant to at least one of the FY26 JWMRP focus areas.Distinctive Features:To be eligible for JWMRP funding, applicants/offerors must have already received DOD/DOW core or DOD/DOW Congressional Special Interest funding.An MMRDA Clinical Research or Clinical Trial Option (MMRDA-CRCTO) is available to specifically support clinical research/observational studies, all phases of clinical trials/interventional studies, and/or correlative studies in support of the development of promising pharmaceutical or biologic candidates, medical devices and technologies. Applicants/offerors should select MMRDA-CRCTO when the application/proposal involves research that includes any human subjects, human biological samples (prospective or retrospective) or human data sets. Note: If selecting this option, applicants must submit additional relevant application/proposal materials.

Buyer: Registerenheten i Brønnøysund | Notice type: cn-standard | Procedure: restricted | Contract: services | Deadline: 2026-11-17

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) along with other participating Institutes encourages submission of applications proposing to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate cancer risk and related outcomes (e.g., risk prediction or reduction, survival, or response to treatment, etc.). The goal of this initiative is to address key scientific questions relevant to cancer by supporting the analysis of existing clinical, environmental, surveillance, health services, vital statistics, behavioral, lifestyle, genomic, and molecular profiles data. Applicants are encouraged to leverage and perform innovative analyses of the existing data. Applications may include new research aims that are being addressed with existing data, new or advanced methods of analyses, or novel combinations and integration of datasets that allow the exploration of important scientific questions in cancer research.

The goal of this notice of funding opportunity (NOFO) is to support feasibility trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) for conditions that have been identified by NCCIH as high-priority research topics. This funding opportunity is intended to support feasibility clinical trials that provide new information that are scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIHs mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent competitive full-scale clinical trial. Under this R34, the data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: examining feasibility and acceptability of interventions lacking published data; tailoring or adapting the content or structure of an intervention to a specific population, modality, or setting; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention, and data collection procedures; refining and assessing the feasibility of protocolized multi-component interventions; or examining acceptability and adherence of control conditions. The subsequent...

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy or effectiveness of complementary and integrative health interventions in NCCIH- designated areas of high research priority. Applications submitted under this NOFO are expected to propose a remotely delivered and conducted fully powered clinical trial with no in-person contact between research staff and study participants and may utilize mHealth tools or technologies. Applicants must provide justification for the remotely delivered approach and provide preliminary data on the feasibility and safety of the approach, along with evidence that the intervention has promise of clinical benefit. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO.

This notice of funding opportunity (NOFO) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH-designated areas of high research priority. Applications submitted under this NOFO are expected to propose a multisite feasibility clinical trial that will provide new information that is scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIHs mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R01) research is scientifically necessary to design or plan the subsequent fully powered, full-scale clinical trial. Under this R01, the data collected should be used to fill gaps in scientific knowledge, including, but not limited to the following: assessing whether the intervention can be delivered with fidelity across sites; demonstrating feasibility of recruitment, accrual, and randomization of participants across sites; demonstrating participant adherence to the intervention, as well as retention of participants throughout the study across sites; refining and assessing the feasibility of protocolized multimodal interventions, and/or demonstrating feasibility of data collection across sites in preparation for a future fully powered, multisite efficacy or effectiveness trial. The need for multisite fe...

This Notice of Funding Opportunity (NOFO) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The intent of this NOFO is to support research that advances (1) prevention approaches to reduce prenatal alcohol exposure and the incidence of FASD and that (2) interventions for FASD. These objectives will be accomplished with the Exploratory/Developmental Phased Award (R61/R33) mechanism, clinical trial optional. The R61 phase will support pilot studies or secondary data analysis for hypothesis development and feasibility, and research testing the hypotheses can be expanded in the R33 phase. The transition to the R33 phase will be determined by NIAAA program staff after evaluation of the achievement of specific milestones set for the R61 phase. Highest priority will be given to applications with clinical trials. Applicants interested in planning clinical trials or adding to current projects may also consider NOFO (TEMP-23832, the R34 option).

The U.S. NSF Directorate for Technology, Innovation and Partnerships (NSF TIP) partners across sectors to advance three primary focus areas – accelerating technology translation and development, fostering regional innovation and economic growth, and preparing the American workforce for future high-wage jobs in STEM fields. The translation of research to practice ensures that the insights and innovations developed through scientific study and experimentation have tangible, positive impacts for the Nation. These impacts include improving the quality of life, promoting economic and job growth, ensuring national security, and maintaining global competitiveness. Indeed, scientific and engineering breakthroughs have the potential to address critical societal challenges in industries such as aerospace, agriculture, communications, education, energy, healthcare, national security, and transportation – but the translation of discoveries and innovations from the laboratory to society often takes many forms including non-linear pathways. The NSF TTP program was developed with several goals in mind: To identify and support use-inspired research and translational activities enabling a continuum from foundational research to practice; To develop partnerships and collaborations between institutions of higher education and other entities (e.g., industry, state/local/national government agencies, philanthropies, open-source ecosystems, for-benefit, for-profit and non-profit organizations, international organizations, etc.); To promote and advance the education and training of students and p...

Buyer: Gemeente Smallingerland | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-18

Buyer: Gemeente Smallingerland | Notice type: cn-standard | Procedure: open | Contract: supplies | Deadline: 2026-11-18

The purpose of this NOFO is to invite Research Project (R01) applications that propose to study the ethical, legal, and social implications (ELSI) of human genetics and genomics. Applications may propose studies using either single or mixed methods. Approaches may include but are not limited to empirical qualitative and quantitative methods, as well as conceptual, legal, and normative analyses. Direct involvement of key stakeholders where appropriate is encouraged. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Applications without a PEDP will not be reviewed.

The purpose of this NOFO is to invite Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal, and social implications (ELSI) of human genetics and genomics. Applications may propose studies using either single or mixed methods. Approaches may include but are not limited to empirical qualitative and quantitative methods, as well as conceptual, legal, and normative analyses. Direct involvement of key stakeholders where appropriate is encouraged. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information. 

The NSF FINDERS FOUNDRY program supports collaboration among K-12 educators, technologists, and researchers to develop innovative solutions to persistent challenges in learning and workforce development. These challenges are identified by K-12 students, families, and educators. The program aims to create and scale evidence-based practices, tools, and technologies that improve learning outcomes and prepare students for a digital, Artificial Intelligence (AI)-driven future. A key focus is early exposure to AI to build curiosity, understanding, and readiness for future careers. The program encourages partnerships across sectors - schools, universities, industry, government, and nonprofits - to co-design responsive, technology-based solutions. NSF FINDERS FOUNDRY program includes two phases: Planning and Development. Planning proposals help teams explore one of several focus areas. Only teams awarded Planning grants may submit Development proposals, which support the growth and implementation of promising ideas. The program aligns with national priorities, including the Executive Order 14277, “Advancing Artificial Intelligence Education for American Youth” (April 23, 2025), and the CHIPS and Science Act of 2022, Public Law 117-167, Sections 10381-10383 and 10395.

Summary: The Orthopaedic Research Program (ORP) Applied Research Award (ARA) seeks applied research applications focused on advancing optimal treatment and restoration of function for individuals with orthopaedic injuries sustained during combat or service-related activities.Distinctive Features: • Applied research is defined as work that refines concepts and ideas into potential solutions with a view toward evaluating technical feasibility of promising new knowledge products, pharmacologic agents, behavioral and rehabilitation interventions, diagnostic and therapeutic techniques, clinical guidance and/or emerging approaches and technologies.• Preliminary data is required.• Military relevance: the ORP expects that research findings benefit Service Members, their families, Veterans and the general public.• Clinical research is not allowed.

Summary: The fiscal year 2026 (FY26) Orthopaedic Research Program (ORP) Clinical Research Award (CRA) seeks clinical research that evaluates orthopaedic-specific factors and interventions. The ORP intends for research supported by this mechanism to generate clinically useful evidence with potential to optimize patient outcomes and inform clinical care or policy. Applications must address how the proposed research will impact patient care and reduce the burden of orthopaedic injury and sequela. The ORP expects that research findings benefit Service Members, their families, Veterans and the general public. To meet the intent of the award mechanism, applications must specifically address at least one of the FY26 ORP CRA Focus Areas.Distinctive Features: ·        The CRA offers two research levels.Research Level 1 (RL1) supports clinical research in the following FY26 ORP focus areas:·        Ligamentous Trauma·        Osseointegration Outcomes·        Return-to-Duty Strategies·        Military Women’s HealthResearch Level 2 (RL2) supports clinical trials in the following FY26 ORP focus areas:·        Ligamentous Trauma·        Limb Stabilization and Protection·        Return-to-Duty Strategies

Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Resource and Community Development Award (RCDA) supports the development of research resources and clinical or preclinical datasets that will advance the field of rare cancers research and ultimately improve outcomes for individuals with rare cancers. Research supporting this funding opportunity should fill one of the following major gaps:Lack of research and clinical resources, including patient tissues, cell and tumor models.Lack of communication and dissemination strategies within scientific and patient communities for sharing rare cancers research and clinical findings.Lack of infrastructure for sharing data and other resources.Lack of therapeutics and mechanistic research to inform treatment development.Distinctive Features:Documentation of plans for engagement and partnerships with Patient Advocates throughout the life cycle of the research study from development of the research question through execution of the study.Community building and enhancement are key components.A description of the dissemination and sustainability of the platform for scientific and/or clinical and patient community is required.Preliminary data are not required but may be included to address feasibility.

Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Idea Development Award (IDA) promotes ideas that are ready for further development and have the potential to yield high-impact findings and new avenues of investigation.Distinctive Features:The RCRP encourages applicants to include an exploratory aim or sub-aim to support any necessary discovery-driven research.Preliminary data with disease-specific rationale are required. However, these data do not necessarily need to originate from studies of the proposed rare cancer type(s)/subtype(s) under study.Research should have high potential impact on rare cancers and the patient community.

Summary: The fiscal year 2026 (FY26) Combat Readiness – Medical Research Program (CRRP) Translational Research Award (TRA) supports hypothesis-driven innovative, high-impact translational research that will accelerate the movement of promising ideas and/or technologies in trauma care into solutions to maximize casualty survivability, improve patient care closer to the point of injury and/or trauma care guidelines. Preliminary data are required. Research using well-validated animal models is allowed.Distinctive Features:• **NEW for FY26** An investigator may be named as the Principal Investigator (PI) on only one FY26 CRRP TRA application.• Research supported by the FY26 CRRP TRA must represent a mature, translational research effort with a minimum biomedical technology readiness level (TRL) of 4 or knowledge readiness level (KRL) of 4.

Buyer: Všeobecná fakultní nemocnice v Praze | Notice type: cn-standard | Procedure: restricted | Contract: supplies | Deadline: 2026-11-19

This NOFO encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies being conducted within StrokeNet. Successful applicants will collaborate and conduct the study within the NIH StrokeNet. Following peer review, NINDS will prioritize studies among the highest scoring to be conducted in the NIH StrokeNet infrastructure. The NIH StrokeNet National Coordinating Center (NCC) will work with the successful applicant to implement the proposed study efficiently and the National Data Management Center (NDMC) will provide statistical and data management support. The NIH StrokeNet Regional Coordinating Centers (RCCs) and their affiliated clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.

The purpose of this Notice of Funding Opportunity (NOFO) is to invite applications that bundle independent protocols for phase 1 clinical trials with phase 1b/phase 2a clinical trials to streamline the early-stage evaluation of promising pharmacological interventions for Alzheimer's disease (AD) and Alzheimer's disease-related Dementias (ADRD). Candidate interventions evaluated through this program, which can include small molecules or biologics for example, must engage non-amyloid/non-tau mechanisms and aim to address cognitive and/or neuropsychiatric symptoms in individuals across the spectrum from pre-symptomatic to more severe stages of disease. This NOFO uses the UG3/UH3 phased award mechanism and proposals must include prespecified, go/no-go safety and tolerability milestones that gate the advance from phase 1 to latter stages of clinical development.

Summary: The fiscal year 2026 Toxic Exposures Research Program (TERP) Investigator-Initiated Research Award (IIRA) is intended to support studies that will make an important contribution toward research and/or patient care for diseases or conditions associated with military-related toxic exposures. Research projects may focus on any phase of research from basic laboratory research through translational research, including preclinical studies in animal models and human subjects, as well as correlative studies associated with an existing clinical trial. New Approach Methodologies may also be used. https://cdmrp.health.mil/pubs/press/2026/terppreann

Summary: The intent of the fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Translational Research Award (TRA) is to support translational research that will accelerate the movement of promising ideas in military-related toxic exposure research into clinical applications, including health care products, interventions, technologies and/or clinical practice guidelines. Translational research may be defined as an integration of basic science and clinical observations. New Approach Methodologies may also be used. Applications should provide evidence for the reciprocal transfer of information between basic and clinical science, or vice versa, in developing and implementing the research plan.  Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP TRA includes a Partnering Principal Investigator Option (PPIO). One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising ideas into clinical applications. Partnering should significantly advance the research beyond what would be possible through individual efforts. https://cdmrp.health.mil/pubs/press/2026/terppreann

Summary: The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations.  Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP CTA includes a Partnering Principal Investigator Option (PPIO). One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising interventions/​knowledge products into clinical applications. Partnering should significantly advance the research beyond what would be possible through independent efforts. https://cdmrp.health.mil/pubs/press/2026/terppreann